title: Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.
abstract: BACKGROUND
  The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive. However, during early months of use unscheduled vaginal bleeding is common, sometimes leading to discontinuation. This study aimed to determine whether intermittent administration of progesterone receptor modulator CDB-2914 would suppress unscheduled bleeding during the first 4 months after insertion of the LNG-IUS.
  
  
  METHODS
  CDB-2914 150 mg, in divided doses, or placebo tablets, were administered over three consecutive days starting on Days 21, 49 and 77 after LNG-IUS insertion, in a double-blind randomized controlled trial of women aged 19-49 years, newly starting use of LNG-IUS. Daily bleeding diaries were completed for 6 months, and summarized across blocks as percentage days bleeding/spotting (BS%).
  
  
  RESULTS
  Of 69 women randomized to receive CDB-2914, and 67 placebo, 61 and 55, respectively, completed the trial. BS% decreased with time in both arms, but showed a much steeper treatment-phase gradient in the placebo arm (P < 0.0001), so that a benefit of CDB-2914 in the 28 days after first treatment (-11% points, 95% CI -19 to -2), converted to a disadvantage by 64 days after the third treatment (+10% points, 95% CI 1-18).
  
  
  CONCLUSIONS
  The effect of CDB-2914 on BS% was initially beneficial but then by third treatment was disadvantageous. Nevertheless, only 3% (4/136) of all women discontinued LNG-IUS. These findings give insight into possible mechanisms and suggest future research directions. ISRCTN Trial no. ISRCTN58283041; EudraCT no. 2006-006511-72.
authors.affiliation: Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK.
authors.forename: P
authors.initials: P
authors.lastname: Warner
authors.forename: A
authors.initials: A
authors.lastname: Guttinger
authors.forename: A F
authors.initials: AF
authors.lastname: Glasier
authors.forename: R J
authors.initials: RJ
authors.lastname: Lee
authors.forename: S
authors.initials: S
authors.lastname: Nickerson
authors.forename: R M
authors.initials: RM
authors.lastname: Brenner
authors.forename: H O D
authors.initials: HO
authors.lastname: Critchley
mesh_terms: D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage*; D008796:Metrorrhagia / Q000517:prevention & control*; D008875:Middle Aged; D009649:Norpregnadienes / Q000627:therapeutic use*; D011980:Receptors, Progesterone / Q000187:drug effects
chemical_list: D003271:Contraceptive Agents, Female; D009649:Norpregnadienes; D011980:Receptors, Progesterone; D016912:Levonorgestrel; C094854:ulipristal